• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分枝杆菌脓肿感染的临床结果和药敏试验。

Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.

机构信息

Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

出版信息

J Microbiol Immunol Infect. 2010 Oct;43(5):401-6. doi: 10.1016/S1684-1182(10)60063-1.

DOI:10.1016/S1684-1182(10)60063-1
PMID:21075707
Abstract

BACKGROUND/PURPOSE: Mycobacterium abscessus is the most resistant and rapidly growing mycobacterium and causes a wide range of clinical infectious diseases. The relationship between antimicrobial susceptibility and clinical outcome needs to be further evaluated.

METHODS

Forty M. abscessus isolates were obtained from clinical specimens of 40 patients at the Taichung Veterans General Hospital from January 2006 to December 2008. Antimicrobial susceptibility testing was performed using the broth microdilution method according to the recommendations of the National Committee for Clinical Laboratory Standards. The clinical manifestations and outcomes were reviewed from medical records.

RESULTS

Twenty-two patients were diagnosed with M. abscessus infection. Cough (86.3%), hemoptysis (31.8%) and fever (18.1%) were the most common symptoms. The radiographic findings included reticulonodular opacities (50.0%), consolidation (31.8%) and cavitary lesions (18.1%). The 40 isolates were susceptible to amikacin (95.0%), cefoxitin (32.5%), ciprofloxacin (10.0%), clarithromycin (92.5%), doxycycline (7.5%), imipenem (12.5%), moxifloxacin (22.5%), sulfamethoxazole (7.5%) and tigecycline (100%). The rate of treatment failure was 27.3% at the end of the 12(th) month after the start of treatment, although these patients were treated with a combination of clarithromycin and other antimicrobial agents.

CONCLUSION

M. abscessus is naturally susceptible to clarithromycin and amikacin, variably susceptible to cefoxitin and imipenem, and resistant to most other antimicrobial drugs. Combination therapy with clarithromycin, amikacin and other active antimicrobial agents may lead to clinical improvement; however, the rate of treatment failure is still high.

摘要

背景/目的:脓肿分枝杆菌是最具耐药性和生长最快的分枝杆菌,可引起广泛的临床感染性疾病。需要进一步评估抗菌药物敏感性与临床结局之间的关系。

方法

2006 年 1 月至 2008 年 12 月,从台中荣民总医院 40 例患者的临床标本中获得 40 株脓肿分枝杆菌分离株。根据美国临床实验室标准化委员会的建议,采用肉汤微量稀释法进行抗菌药物敏感性试验。从病历中回顾临床表现和结局。

结果

22 例患者被诊断为脓肿分枝杆菌感染。最常见的症状为咳嗽(86.3%)、咯血(31.8%)和发热(18.1%)。影像学表现包括网状结节状阴影(50.0%)、实变(31.8%)和空洞病变(18.1%)。40 株分离株均对阿米卡星(95.0%)、头孢西丁(32.5%)、环丙沙星(10.0%)、克拉霉素(92.5%)、强力霉素(7.5%)、亚胺培南(12.5%)、莫西沙星(22.5%)、复方磺胺甲噁唑(7.5%)和替加环素(100%)敏感。虽然这些患者接受了克拉霉素和其他抗菌药物的联合治疗,但在治疗开始后第 12 个月结束时,治疗失败率仍为 27.3%。

结论

脓肿分枝杆菌天然对克拉霉素和阿米卡星敏感,对头孢西丁和亚胺培南的敏感性不同,对大多数其他抗菌药物耐药。克拉霉素、阿米卡星和其他有效抗菌药物的联合治疗可能会导致临床改善,但治疗失败率仍很高。

相似文献

1
Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.分枝杆菌脓肿感染的临床结果和药敏试验。
J Microbiol Immunol Infect. 2010 Oct;43(5):401-6. doi: 10.1016/S1684-1182(10)60063-1.
2
[Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].[龟分枝杆菌和脓肿分枝杆菌的药敏分析及Etest药敏试验评估]
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):567-71.
3
Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.替加环素与克拉霉素或阿米卡星联合对台湾地区快速生长分枝杆菌的协同作用。
Int J Antimicrob Agents. 2013 Mar;41(3):218-23. doi: 10.1016/j.ijantimicag.2012.10.021. Epub 2013 Jan 9.
4
Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.非结核分枝杆菌性眼部感染——脓肿分枝杆菌与马西利亚分枝杆菌临床及微生物学特征比较
PLoS One. 2015 Jan 12;10(1):e0116236. doi: 10.1371/journal.pone.0116236. eCollection 2015.
5
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].[快速生长分枝杆菌的抗菌药敏性评估]
Mikrobiyol Bul. 2023 Apr;57(2):220-237. doi: 10.5578/mb.20239917.
6
Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.从脓肿分枝杆菌中区分马赛分枝杆菌的临床意义。
Am J Respir Crit Care Med. 2011 Feb 1;183(3):405-10. doi: 10.1164/rccm.201003-0395OC. Epub 2010 Sep 10.
7
In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.伊朗非结核分枝杆菌的体外抗菌药敏性
Microb Drug Resist. 2016 Mar;22(2):172-8. doi: 10.1089/mdr.2015.0134. Epub 2015 Oct 15.
8
CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates.脓肿分枝杆菌复合体引起的中枢神经系统感染:分离株的临床特征和药敏结果。
J Antimicrob Chemother. 2012 Jan;67(1):222-5. doi: 10.1093/jac/dkr420. Epub 2011 Oct 6.
9
Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.呼吸道常见临床相关非结核分枝杆菌分离株的抗菌药敏和最小抑菌浓度分布。
Ann Med. 2022 Dec;54(1):2500-2510. doi: 10.1080/07853890.2022.2121984.
10
Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.脓肿分枝杆菌、龟分枝杆菌和偶发分枝杆菌肉汤微量稀释法药敏试验结果的多中心可重复性。
J Clin Microbiol. 1999 Jun;37(6):1676-82. doi: 10.1128/JCM.37.6.1676-1682.1999.

引用本文的文献

1
Mutations in the transcriptional regulator MAB_2885 confer tedizolid and linezolid resistance through the MmpS-MmpL efflux pump MAB_2302-MAB_2303 in Mycobacterium abscessus.转录调节因子MAB_2885中的突变通过脓肿分枝杆菌中的MmpS-MmpL外排泵MAB_2302-MAB_2303赋予替加环素和利奈唑胺耐药性。
PLoS Pathog. 2025 May 30;21(5):e1013190. doi: 10.1371/journal.ppat.1013190. eCollection 2025 May.
2
Concurrent Coccidioidomycosis and Infection in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病合并球孢子菌病感染
J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251334229. doi: 10.1177/23247096251334229. Epub 2025 Apr 28.
3
Disseminated Mycobacterium abscessus infection with idiopathic CD4+ T-lymphocytopenia: a case report and review of the literature.
播散性脓肿分枝杆菌感染合并特发性CD4+ T淋巴细胞减少症:一例病例报告及文献复习
J Med Case Rep. 2024 Dec 31;18(1):645. doi: 10.1186/s13256-024-05009-w.
4
Contribution of machine learning for subspecies identification from Mycobacterium abscessus with MALDI-TOF MS in solid and liquid media.基于 MALDI-TOF MS 的机器学习在固体和液体培养基中对脓肿分枝杆菌亚种鉴定的贡献。
Microb Biotechnol. 2024 Sep;17(9):e14545. doi: 10.1111/1751-7915.14545.
5
Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.奥马环素治疗脓肿分枝杆菌感染:有效性评价、治疗地位及应用考量。
BMC Infect Dis. 2022 Nov 22;22(1):874. doi: 10.1186/s12879-022-07857-7.
6
urinary tract infection in an immunocompetent host: A case report and literature review.免疫功能正常宿主的尿路感染:一例病例报告及文献综述
IDCases. 2022 Jun 15;29:e01538. doi: 10.1016/j.idcr.2022.e01538. eCollection 2022.
7
Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.非结核分枝杆菌感染的治疗药物监测。
Clin Pharmacokinet. 2021 Jun;60(6):711-725. doi: 10.1007/s40262-021-01000-6. Epub 2021 Mar 10.
8
infection after facial injection of argireline: A case report.面部注射阿基瑞林后感染:一例报告。
World J Clin Cases. 2021 Mar 16;9(8):1996-2000. doi: 10.12998/wjcc.v9.i8.1996.
9
A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility.一种新型 DNA 层析法区分脓肿分枝杆菌亚种和大环内酯类药物敏感性
EBioMedicine. 2021 Feb;64:103187. doi: 10.1016/j.ebiom.2020.103187. Epub 2021 Jan 11.
10
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.非结核分枝杆菌肺病的治疗:美国胸科学会/欧洲呼吸学会/欧洲临床微生物学与感染病学会/美国感染病学会官方临床实践指南
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.